“The MD Anderson GCC will perform extensive genomic, transcriptomic and proteomic analysis of patients’ samples collected through multiple programs at NCI,” said J.C. Zenklusen, Ph.D., director of the NCI’s The Cancer Genome Atlas (TCGA) program. “It will support important NCI initiatives such as the Exceptional Responders Initiative, the ALCHEMIST precision medicine trials, and the Cancer Driver Discovery Project.”
“MD Anderson has been at the forefront of proteomic investigation and it is an honor to be selected as a site for this notable center,” said Ethan Dmitrovsky, M.D., provost and executive vice president.
Mills believes the efforts could “encompass as many as 25,000 patient samples.”
“This will provide an incredible information trove linked to high-quality patient outcomes data, genomic, epigenomic and proteomic data. It’s a great example of how working together can yield important clinical understanding.”
The other Genome Characterization Center is based at the Broad Institute in Boston.